By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Brain Diseases are discussed in a new report. According to news reporting from London, United Kingdom, by NewsRx journalists, research stated, "Neuropeptides play an important role in modulating seizures and epilepsy. Unlike neurotransmitters which operate on a millisecond time-scale, neuropeptides have longer half lives; this leads to modulation of neuronal and network activity over prolonged periods, so contributing to setting the seizure threshold."
The news correspondents obtained a quote from the research from University College London, "Most neuropeptides are stored in large dense vesicles and co-localize with inhibitory interneurons. They are released upon high frequency stimulation making them attractive targets for modulation of seizures, during which high frequency discharges occur. Numerous neuropeptides have been implicated in epilepsy; one, ACTH, is already used in clinical practice to suppress seizures. Here, we concentrate on neuropeptides that have a direct effect on seizures, and for which therapeutic interventions are being developed. We have thus reviewed the abundant reports that support a role for neuropeptide Y (NPY), galanin, ghrelin, somatostatin and dynorphin in suppressing seizures and epileptogenesis, and for tachykinins having pro-epileptic effects. Most in vitro and in vivo studies are performed in hippocampal tissue in which receptor expression is usually high, making translation to other brain areas less clear."
According to the news reporters, the research concluded: "We highlight recent therapeutic strategies to treat epilepsy with neuropeptides, which are based on viral vector technology, and outline how such interventions need to be refined in order to address human disease."
For more information on this research see: Neuropeptides in epilepsy. Neuropeptides, 2013;47(6):467-475. Neuropeptides can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Neuropeptides - www.elsevier.com/wps/product/cws_home/623063)
Our news journalists report that additional information may be obtained by contacting S. Kovac, UCL, UCL Inst Neurol, London, United Kingdom (see also Brain Diseases).
Keywords for this news article include: Biotechnology, London, Epilepsy, Seizures, Gene Therapy, Therapeutics, Neuropeptides, United Kingdom, Bioengineering, Brain Diseases, Nerve Tissue Proteins, Neurologic Manifestations, Central Nervous System Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC